Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That Its European Partner, Daiichi Sankyo Europe, Reported Final 2-year Follow-up Data From the German Cohort of the Multinational, European Observational MILOS Study.
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Express News | Esperion EU Partner Reports Final Real-World Results From Milos German Cohort Demonstrating Strong Increase in Ldl-C Goal Achievement With Addition of Bempedoic Acid
Esperion EU Partner Reports Final Real-World Results From MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid